

Disclosures

Management guidelines for HIV-related Co-morbidities Result in Increased Screening but no change in Primary Prevention Implementation

Trevillyan JM, Dart A, Topliss DJ, Walker RG, Whiting SE, Hoy JF


ASHM Friday 18th September 2015



- No authors have any significant conflicts of interest relevant to this work
- Professor Jennifer Hoy's institution has received reimbursement for her participation in Advisory Boards for Gilead Science, Merck Sharp & Dohme, ViiV Healthcare and Abbott.

Background


- Serious non-AIDS events are of increasing importance in the modern antiretroviral era



Rodger et al. AIDS 2013;27(6):973




The changing demographic of HIV infection



Smit et al. Lancet ID 2015; 15:810-18




"Multi-morbidity" will be increasingly common



Smit et al. Lancet ID 2015; 15:810-18



Decreasing rates of AMI over time in HIV+ patients



Klein et al. CID 2015;60(8):1278



Definition: Recommended Statin Therapy

- The National Vascular Disease Prevention Alliance (NVDPA); www.cvdcheck.org.au
- Any patient (regardless of cholesterol) with:
 - Coronary artery disease
 - Peripheral vascular disease
 - Stroke
 - Chronic kidney impairment (eGFR < 45ml/min)
 - Absolute risk score > 15%
 - Diabetes if > 60 years old
 - Total cholesterol > 7.5 mmol/L
 - Persistent hypertension (SBP ≥ 180 mmHg)



Definition: Recommended Statin Therapy

- Any patient with risk score 10 -15% AND:
 - Family history of coronary artery disease in 1st degree relative
 - Persistent hypertension ≥ 160mmHg
 - Aboriginal descent

Inadequate statin therapy

- Patient currently receiving statin therapy and total cholesterol >4.0 mmol/L, *or*
- Patient inappropriately not on a statin



Statistical Methods

- Results were summarized by group using Fisher's exact or chi-squared tests as appropriate
- Mann Whitney U test for continuous data
- Continuous variables described as medians and interquartile ranges
- All statistical analyses performed on Stata 11.0/IC (College Station, Texas)
- The project was approved by the Alfred Ethics committee (Project Number 167-13)




Participant Characteristics

	Pre Intervention
n	100
Male	93 (93%)
Age, years	49 (38 - 55)
Smoking status	
Never smoked	24 (24%)
Ex-Smoker	5 (5%)
Current Smoker	38 (38%)
Not documented	33 (33%)
Diabetic status	
Non-diabetic	58 (58%)
Diabetic	6 (6%)
Not screened	36 (36%)
History of CVD ^a	7 (7%)
Framingham Risk score, %	10 (6.5 - 13)
eGFR, ml/min	85 (75 - >90)
Blood pressure recorded	65 (65%)
Systolic BP, mmHg	125 (120 - 132)




Cholesterol


- 81% pre and 83% post-intervention had fasting cholesterol levels available (p = 0.713)



Compliance with guidelines for statin use



Adequacy of Statin Therapy




MONASH University



Management of Hypertension

- 23 participants pre-intervention and 17 post intervention were receiving an antihypertensive


Patients with SBP ≥ 140mmHg



MONASH University




Mean Systolic Blood Pressure



MONASH University



High proportion of patients with borderline renal function as estimated by eGFR



MONASH University



Limitations

- Small sample size
- Retrospective design
- Homogeneous patient population
- Potentially not long enough between intervention and post-audit for lipid or blood pressure changes to take effect
- Equally the durability of improved attention to screening for cardiovascular risk factors post intervention is not known

MONASH University



Conclusions

- Improvements in screening for cardiovascular risk factors can be achieved with education tools
- These alone are not sufficient to improve the implementation or optimisation of primary preventative therapies
- Changes to the model of HIV care provision may be what's needed

MONASH University



Acknowledgements

- J Trevillyan was supported by an Australian Postgraduate Award
- An abbreviated version of this data was published in *AIDS* 2015;29 :745

Janine.Trevillyan@monash.edu

